Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into ...

Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, ...

FDA approved the drug Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that has not ...

The US Food and Drug Administration recently approved an alternative treatment option for patients with BCG-unresponsive high ...

The decision gives certain patients whose cancer has resisted BCG therapy another treatment option aimed at preserving the bladder. Here’s who qualifies and what the evidence shows.

The agency used a 'new approach' to broaden the drug's indication to include patients with BCG-unresponsive non-muscle invasive bladder cancer whose tumors are papillary-only.

ImmunityBio (IBRX) stock rises as FDA expands ANKTIVA approval to papillary-only bladder cancer, widening treatment access ...

Researchers developed a urine test that detects bladder cancer, predicts which patients will benefit from immunotherapy ...

The Food and Drug Administration has expanded its approved indication for ImmunityBio's Anktiva, a bladder-cancer treatment. The new indication expands Anktiva to be used in combination with Bacillus ...

The vast majority of Australia's bladder cancer cases are in men, but experts are concerned about the number of women ...

The FDA expanded approval of Anktiva for bladder cancer. The agent is the first approved treatment for BCG-unresponsive, high ...

The Food and Drug Administration expanded approval of ImmunityBio's nogapendekin alfa inbakicept-pmln, marketed as Anktiva, ...